Valuation: AbbVie Inc.

Capitalization 340B 325B 307B 270B 483B 29,582B 536B 3,645B 1,351B 12,349B 1,276B 1,251B 51,654B P/E ratio 2025 *
26.3x
P/E ratio 2026 * 21.7x
Enterprise value 393B 376B 354B 311B 558B 34,140B 619B 4,206B 1,560B 14,252B 1,473B 1,443B 59,613B EV / Sales 2025 *
6.62x
EV / Sales 2026 * 5.99x
Free-Float
96.39%
Yield 2025 *
3.34%
Yield 2026 * 3.49%
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.75%
1 week+3.10%
Current month+6.72%
1 month+14.39%
3 months+18.95%
6 months+1.21%
Current year+10.44%
More quotes
1 week
190.39
Extreme 190.39
197.02
1 month
168.06
Extreme 168.06
197.02
Current year
168.06
Extreme 168.06
197.02
1 year
153.58
Extreme 153.58
207.32
3 years
130.96
Extreme 130.9601
207.32
5 years
62.55
Extreme 62.55
207.32
10 years
45.45
Extreme 45.45
207.32
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 2024-06-30
Director of Finance/CFO 58 2022-06-22
Chief Tech/Sci/R&D Officer - 2002-12-31
Director TitleAgeSince
Chairman 71 2012-12-31
Director/Board Member 64 2012-12-31
Director/Board Member 73 2012-12-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+1.75%+3.10%+10.57%+35.37% 340B
+1.53%-1.34%+9.61%+255.73% 760B
-0.74%+0.49%-1.00%-6.74% 376B
+3.09%-4.61%-31.01%+74.47% 355B
+0.20%+1.48%+29.23%-14.52% 262B
+0.63%+0.60%+16.78%+32.18% 229B
+0.34%-3.60%-34.82%+9.08% 210B
+0.45%-0.79%+8.74%+20.24% 210B
+0.56%-0.68%+3.21%+32.08% 156B
+0.12%-1.20%-7.46%-47.73% 145B
Average +0.67%-1.47%+0.38%+39.02% 304.45B
Weighted average by Cap. +0.91%-1.86%+1.63%+78.24%
See all sector performances

Financials

2025 *2026 *
Net sales 59.35B 56.73B 53.53B 47.04B 84.22B 5,157B 93.44B 635B 236B 2,153B 222B 218B 9,004B 63.95B 61.13B 57.67B 50.69B 90.74B 5,556B 101B 685B 254B 2,319B 240B 235B 9,701B
Net income 11.88B 11.36B 10.72B 9.42B 16.86B 1,033B 18.71B 127B 47.17B 431B 44.54B 43.65B 1,803B 14.84B 14.19B 13.38B 11.76B 21.06B 1,289B 23.36B 159B 58.91B 538B 55.62B 54.51B 2,251B
Net Debt 52.46B 50.14B 47.31B 41.58B 74.43B 4,558B 82.58B 562B 208B 1,903B 197B 193B 7,958B 42.53B 40.66B 38.36B 33.71B 60.35B 3,696B 66.96B 455B 169B 1,543B 159B 156B 6,453B
More financial data * Estimated data
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).
Employees
55,000
More about the company
Date Price Change Volume
25-02-18 196.25 $ +1.75% 6,064,609
25-02-14 192.87 $ -0.30% 3,976,903
25-02-13 193.45 $ +0.23% 4,108,920
25-02-12 193.00 $ +0.61% 4,525,009
25-02-11 191.83 $ +0.78% 3,977,033

Delayed Quote Nyse, February 18, 2025 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
196.25USD
Average target price
204.90USD
Spread / Average Target
+4.41%
Consensus

Quarterly revenue - Rate of surprise